Boston Scientific’s (NYSE:BSX) lead-free S-ICD cardiac rhythm management made another strong showing, with results from an analysis of more than 880 patients showing relatively few complications.

In a poster session at today’s Heart Rhythm 2014, the Heart Rhythm Society’s 35th Annual Scientific Sessions, researchers unveiled nearly 2 years of data from the 2 largest S-ICD databases, saying that the device performed well relative to traditional implantable cardioverter defibrillators.

The study a device removal rate below 3%, with just over 10% of patients experiencing inappropriate shocks, a rate that they called "comparable to transvenous ICDs."

That’s more good news for Boston Scientific, which acquired the S-ICD technology in June 2012 when it acquired Cameron Health in a deal worth $1.35 billion. 

The device has been making headlines as the 1st FDA-approved lead-free cardiac rhythm implant. The device won U.S. approval in 2012, shortly after the acquisition.

Boston Scientific this year introduced the device in the Asia Pacific region, saying that the company was making inroads with the clinical communities in China, Japan and South Korea. The 1st Asia S-ICD procedure was performed in China by the University of Hong Kong professor of cardiovascular medicine Dr. Hung Fat Tse, Boston Scientific announced in April.

Earlier this year the medtech titan released positive real-world data on the device, which provides cardiac rhythm management without the needs for metallic wires, or leads, to be threaded through the heart.

Boston Scientific isn’t alone in touting a lead-free cardiac implant at this year’s Heart Rhythm Society conference. Rival St. Jude Medical (NYSE:STJ) is touting its Nanostim lead-free pacemaker with a late-breaking presentation scheduled this week to reveal 1-year results from the company’s LEADLESS trial.*

*Correction: This article originally stated that St. Jude Medical’s Nanostim device is an ICD. The Nanostim device is a pacemaker.